Company intelligence / Profile preview

StemPath

Ownership: Private
Development stage: Other

Overview

StemPath developed novel peptide-based therapeutics aimed at stimulating heart and skeletal muscle regeneration by harnessing the body’s natural repair mechanisms. The company received $1 million in private financing in 2006 but has not reported clinical results or further development since then.

Therapeutic areas: OtherCardiovascular
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Genesys Capital Partners

Beyond the preview

Go deeper on StemPath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemPath.

Explore the full profile